Article: MAINTENANCE TREATMENT WITH AVASTIN AND TARCEVA AIDS LUNG CANCER.

Article: Data from the Phase III ATLAS Study Show Tarceva in ...
Cancer Weekly;  June 16, 2009 ;     700+ words ... ... plus placebo group. The ATLAS study was funded by Genentech and ... funding payments for the ATLAS study depending upon, amongst ... inclusion of data from the ATLAS study in the Tarceva label. About Lung Cancer According to the American ...

Article: Phase III Study Showed Tarceva in Combination with Avastin as ...
Business Wire;  February 2, 2009 ;     700+ words ... ... metastatic non-small cell lung cancer (NSCLC). In order ... disease progression. The ATLAS study was funded by Genentech ... funding payments for the ATLAS study depending upon, amongst ... regulatory authorities. About Lung Cancer According to the American ...

Article: World Conference on Lung Cancer Tarceva Survival ...
BIOWORLD Today;  August 4, 2009 ;     700+ words ... ... percent of the U.S. lung cancer population. In this ... analysts, he predicts lung cancer doctors will be slow ... data from the Phase III ATLAS study, which was stopped early ... treatment of choice for lung cancer patients with epidermal ...

Article: Phase III Study Showed Patients Lived Longer Without Advanced ...
Blood Weekly;  June 18, 2009 ;     700+ words ... ... people with advanced lung cancer survive less than one ... lead investigator of the ATLAS study, and Associate Attending ... first-line treatment of lung cancer," said Hal Barron ... therapy." Results of the ATLAS study were featured today during ...

Article: Atlas Study Pinpoints Lunchtime and Primetime as ...
Business Wire;  September 14, 2005 ;     700+ words ...SEATTLE -- Atlas (www.AtlasSolutions.com), a provider of digital marketing technologies and expertise, and an operating unit of aQuantive, Inc. (NASDAQ:AQNT), today released research demonstrating the potential of dayparting on direct response interactive marketing campaigns. E[acute accent]Atlas's

Article: Latest Atlas Study Reveals Cross-Promotion As Key ...
Business Wire;  November 1, 2006 ;     700+ words ...Case Study Shows Nearly 25 Percent of VOD Advertising Viewership Driven by Branded Navigation Unit (BNU) Promotional Spots SEATTLE -- A key risk in long-form video-on-demand (VOD) advertising is producing and hosting content that nobody ends up seeing. Atlas, a provider of digital marketing

Article: Patient enrollment completed in ATLAS study for ...
Pharma Marketletter;  February 28, 2005 ;     700+ words ...Canada's Angiotech Pharmaceuticals says that its corporate partner, Boston Scientific, has completed enrollment in its ATLAS clinical trial. This is the first trial using Boston's new Liberte coronary stent as a platform for its paclitaxel-eluting coronary stent system. Taxus Liberte is the next